A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT ID: NCT06697197
Last Updated: 2026-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
413 participants
INTERVENTIONAL
2025-02-17
2029-01-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
NCT03994601
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
NCT03661632
A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
NCT05625412
A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors
NCT05298592
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
NCT03956680
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1A
BMS-986482
Specified dose on specified days
Part 1B1
BMS-986482
Specified dose on specified days
Nivolumab and rHuPH20
Specified dose on specified days
Part 1B2
BMS-986482
Specified dose on specified days
Nivolumab/relatlimab/rHuPH20
Specified dose on specified days
Part 1B3
BMS-986482
Specified dose on specified days
Bevacizumab
Specified dose on specified days
Part 1C
BMS-986482
Specified dose on specified days
Part 2A
BMS-986482
Specified dose on specified days
Part 2B1
BMS-986482
Specified dose on specified days
Nivolumab and rHuPH20
Specified dose on specified days
Part 2B2
BMS-986482
Specified dose on specified days
Nivolumab/relatlimab/rHuPH20
Specified dose on specified days
Part 2B3
BMS-986482
Specified dose on specified days
Bevacizumab
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986482
Specified dose on specified days
Nivolumab and rHuPH20
Specified dose on specified days
Nivolumab/relatlimab/rHuPH20
Specified dose on specified days
Bevacizumab
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF.
Exclusion Criteria
* Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Irvine (UCI) Health - UC Irvine Medical Center
Irvine, California, United States
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California, United States
Local Institution - 0008
Aurora, Colorado, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Northwell Health/ RJ Zuckerberg Cancer Center
Lake Success, New York, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States
UZ Gent
Ghent, Oost-Vlaanderen, Belgium
Rigshospitalet
Copenhagen, Capital Region, Denmark
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone
Marseille, Bouches-du-Rhône, France
Gustave Roussy
Villejuif, Paris, France
General Hospital of Athens "Laiko"
Athens, Attikí, Greece
Papageorgiou General Hospital of Thessaloniki
Thessaloniki, Thessaloníki, Greece
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
Istituto Clinico Humanitas
Rozzano, Milano, Italy
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL)
Amsterdam, North Holland, Netherlands
Erasmus Medisch Centrum
Rotterdam, , Netherlands
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], Spain
Clinica Universidad de Navarra
Pamplona, Navarre, Spain
Hospital Universitario HM Sanchinarro
Madrid, , Spain
Karolinska Universitetssjukhuset Solna
Solna, Stockholms Län [se-01], Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role: CONTACT
First line of the email MUST contain NCT # and Site #.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Warren Chow, Site 0005
Role: primary
Omid Hamid, Site 0030
Role: primary
Site 0008
Role: primary
Martin Gutierrez, Site 0009
Role: primary
Nagashree Seetharamu, Site 0007
Role: primary
Asim Amin, Site 0011
Role: primary
Cristina Rodriguez, Site 0010
Role: primary
Brant Delafontaine, Site 0017
Role: primary
Kristoffer Rohrberg, Site 0022
Role: primary
Caroline Gaudy, Site 0016
Role: primary
Anna PATRIKIDOU, Site 0012
Role: primary
Dimitrios Ziogas, Site 0038
Role: primary
Georgios Lazaridis, Site 0039
Role: primary
Massimo Di Nicola, Site 0037
Role: primary
Matteo Simonelli, Site 0036
Role: primary
Tim Schutte, Site 0018
Role: primary
Sander Bins, Site 0028
Role: primary
Elena Garralda Cabanas, Site 0033
Role: primary
Ignacio Melero Bermejo, Site 0035
Role: primary
Emiliano Calvo, Site 0034
Role: primary
Lisa Liu, Site 0023
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-516602-28
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1309-0886
Identifier Type: OTHER
Identifier Source: secondary_id
CA236-0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.